Health Economics›Acute myeloid leukemia›Maintenance after first-line therapy

Maintenance after first-line therapy

Acute myeloid leukemia · 13 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Sorafenib monotherapy Variant #04	—	R 37 339	28d	—	—	25	R 549 414 PFS proxy	1
Decitabine monotherapy Variant #01	—	R 32 080	42d	—	~6.7 mo	~2	~R 64 160 PFS proxy · indirect	3
Azacitidine monotherapy Variant #01	—	R 29 332	28d	—	~8.7 mo	~6	~R 175 992 PFS proxy · indirect	11
Gemtuzumab ozogamicin monotherapy Variant #04	—	R 28 653	8d	—	~4.9 mo	~8	~R 229 221 PFS proxy · indirect	1
BDMP-BMP-BAMP-BEVP Variant #01 Partial	—	R 9 613	42d	—	—	~4	~R 10 412 indirect	—
POMP Variant #01	—	R 9 449	30d	—	—	~24	~R 226 776 indirect	—
Cytarabine and Thioguanine Variant #02	—	R 1 954	7d	—	—	~2	~R 3 908 indirect	—
Low-dose Cytarabine monotherapy (LoDAC) Variant #01	—	R 1 249	28d	—	~5.4 mo	~6	~R 7 491 PFS proxy · indirect	11
Vorinostat monotherapy Variant #01 Partial	—	—	28d	~3.1 mo	—	~12	—	1
Placebo Partial	—	—	—	~4.2 mo	~8.0 mo	—	—	145
Observation Partial	—	—	—	—	14.8 mo	—	—	—
Azacitidine oral monotherapy Variant #01 Partial	—	—	28d	—	24.7 mo	2	—	—
Panobinostat monotherapy Variant #01 Partial	—	—	21d	—	—	~2	—	—

13 of 13 regimens shown